Recruiting clinical research volunteers

The Hong Kong United Oncology Centre is currently conducting an international Phase I/II clinical trial. If you are a patient with advanced non-small cell lung cancer (NSCLC) with EGFR and/or HER2 mutations, please contact us. We will conduct an initial assessment to determine your eligibility for entry into this clinical trial. Medication and imaging scans are free of charge. However, patients must understand the purpose of the study and any potential risks involved.

Research name：

An open-label, first-in-human trial of BAY 2927088 for the treatment of participants with advanced non-small cell lung cancer (NSCLC) with EGFR and/or HER2 mutations.

An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
ClinicalTrials.gov Identifier: NCT05099172

Patient eligibility：

Patients with advanced non-small cell lung cancer (NSCLC) with EGFR and/or HER2 mutations

Research remuneration：

Related therapeutic drugs, imaging scans and doctor's consultations are free of charge.

Research process：

If you are eligible to participate in this study, you will use the research drug BAY 2927088 for treatment until the end of treatment or your condition deteriorates.

Related risks：

During the study period, you may have discomfort and risk due to treatment with BAY 2927088. Discomfort and risk may vary from person to person.

Interested participants can contact us through the following methods for further information: WhatsApp: 5518 2992 / Click here: https://wa.me/85255087858

Email: Enquiry@hkuoc.hk

Search for more research projects: https://hkuoc.hk/%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6/
Research Sponsor: Bayer